XML 47 R29.htm IDEA: XBRL DOCUMENT v3.20.2
The Company and Summary of Significant Accounting Policies - Additional Information (Detail)
 6 Months Ended 12 Months Ended
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
ClinicalTrials
shares
Jun. 30, 2019
USD ($)
shares
Jun. 30, 2018
USD ($)
shares
Jun. 30, 2017
May 31, 2020
USD ($)
Targeted or Tracking Stock, Stock [Line Items]            
Number of clinical stage candidates | ClinicalTrials   4        
Number of candidate in an ongoing global registration trial | ClinicalTrials   1        
Short-term investments $ 64,899,000 $ 170,299,000 $ 64,899,000      
Estimated life of the intellectual property   14 years        
Corporate tax rate 21.00% 21.00% 21.00% 28.00% 34.00%  
Non-Cash Tax Expense   $ 0 $ 0 $ 15,870,000    
Deferred Revenue Associated With Remaining Performance Obligation   82,500,000        
Unrecognized tax benefits $ 0 0 0      
Recognition Of Deferred Revenue   14,800,000        
Additional Recognition Of Deferred Revenue   67,700,000        
Revenue Recognised With Performance Obligation   $ 6,600,000 $ 1,700,000      
Common stock subject to repurchase or forfeiture | shares   0 0 0    
Accumulated Losses Since Inception (231,218,000) $ (277,234,000) $ (231,218,000)      
Cash And Cash Equivalents,Short Term Investments And Common Stock Proceeds Receivable   $ 182,600,000        
Changes in unrecognized tax position   An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.        
Impairment of finite lived intangible assets   $ 227,000        
Effective Income Tax Rate Reconciliation, Deduction, Percent   80.00%        
Helsinn License Agreement            
Targeted or Tracking Stock, Stock [Line Items]            
Deferred Revenue Associated With Remaining Performance Obligation $ 2,300,000 $ 1,400,000 2,300,000      
KKC Agreements and Helsinn License Agreement [Member]            
Targeted or Tracking Stock, Stock [Line Items]            
Contract with Customer, Liability, Revenue Recognized   7,800,000 800,000 $ 1,000,000    
S*Bio Patents            
Targeted or Tracking Stock, Stock [Line Items]            
Impairment of finite lived intangible assets   $ 200,000        
Minimum [Member]            
Targeted or Tracking Stock, Stock [Line Items]            
Property and equipment, estimated useful life   3 years        
Maximum            
Targeted or Tracking Stock, Stock [Line Items]            
Property and equipment, estimated useful life   7 years        
KHK License Agreement            
Targeted or Tracking Stock, Stock [Line Items]            
Revenue Recognised With Performance Obligation   $ 21,000,000 $ 900,000      
Termination Of KKC Japan License Agreement And Execution Of KKC License Agreement            
Targeted or Tracking Stock, Stock [Line Items]            
Performance obligation cumulative catch up adjustment   3,100,000        
Kyowa Kirin Co            
Targeted or Tracking Stock, Stock [Line Items]            
Milestone payment receivable current   20,400,000        
Total upfront payment receivable for grant of rights   100,000,000       $ 100,000,000
Kyowa Kirin Co | Potential Payments on Achievement of Development Regulatory and Commercial Milestones [Member]            
Targeted or Tracking Stock, Stock [Line Items]            
Total upfront payment receivable for grant of rights   $ 100,000,000